<VariationArchive VariationID="182847" VariationName="NM_058216.3(RAD51C):c.93del (p.Phe32fs)" VariationType="Deletion" Accession="VCV000182847" Version="50" RecordType="classified" NumberOfSubmissions="14" NumberOfSubmitters="14" DateLastUpdated="2024-07-15" DateCreated="2013-09-13" MostRecentSubmission="2024-06-17">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="180903" VariationID="182847">
      <GeneList>
        <Gene Symbol="RAD51C" FullName="RAD51 paralog C" GeneID="5889" HGNC_ID="HGNC:9820" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>17q22</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="58692573" stop="58735611" display_start="58692573" display_stop="58735611" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="56769962" stop="56811691" display_start="56769962" display_stop="56811691" Strand="+" />
          </Location>
          <OMIM>602774</OMIM>
          <Haploinsufficiency last_evaluated="2020-07-08" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=RAD51C">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-07-08" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=RAD51C">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_058216.3(RAD51C):c.93del (p.Phe32fs)</Name>
      <CanonicalSPDI>NC_000017.11:58692732:GGGG:GGG</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>17q22</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="58692733" stop="58692733" display_start="58692733" display_stop="58692733" variantLength="1" positionVCF="58692732" referenceAlleleVCF="CG" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="56770094" stop="56770094" display_start="56770094" display_stop="56770094" variantLength="1" positionVCF="56770093" referenceAlleleVCF="CG" alternateAlleleVCF="C" />
      </Location>
      <ProteinChange>F32fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.10" sequenceAccession="NC_000017" sequenceVersion="10" change="g.56770097del" Assembly="GRCh37">
            <Expression>NC_000017.10:g.56770097del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_058216.1" sequenceAccession="NM_058216" sequenceVersion="1" change="c.93del">
            <Expression>NM_058216.1:c.93del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.11" sequenceAccession="NC_000017" sequenceVersion="11" change="g.58692736del" Assembly="GRCh38">
            <Expression>NC_000017.11:g.58692736del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_023199.1" sequenceAccession="NG_023199" sequenceVersion="1" change="g.5135del">
            <Expression>NG_023199.1:g.5135del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_047169.1" sequenceAccession="NG_047169" sequenceVersion="1" change="g.4347del">
            <Expression>NG_047169.1:g.4347del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_002876.4" sequenceAccession="NM_002876" sequenceVersion="4" change="c.93del">
            <Expression>NM_002876.4:c.93del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_002867.1" sequenceAccession="NP_002867" sequenceVersion="1" change="p.Phe32fs">
            <Expression>NP_002867.1:p.Phe32fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_058216.3" sequenceAccession="NM_058216" sequenceVersion="3" change="c.93del" MANESelect="true">
            <Expression>NM_058216.3:c.93del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_478123.1" sequenceAccession="NP_478123" sequenceVersion="1" change="p.Phe32fs">
            <Expression>NP_478123.1:p.Phe32fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="NR_103872.2" sequenceAccession="NR_103872" sequenceVersion="2" change="n.135del">
            <Expression>NR_103872.2:n.135del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001619" Type="non-coding transcript variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_314" sequenceAccession="LRG_314">
            <Expression>LRG_314:g.5135del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_314t1" sequenceAccession="LRG_314t1">
            <Expression>LRG_314t1:c.93del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA333753" DB="ClinGen" />
        <XRef Type="Allelic variant" ID="602774.0007" DB="OMIM" />
        <XRef Type="rs" ID="730881942" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_058216.3(RAD51C):c.93del (p.Phe32fs) AND Breast-ovarian cancer, familial, susceptibility to, 3" Accession="RCV000024266" Version="8">
        <ClassifiedConditionList TraitSetID="1881">
          <ClassifiedCondition DB="MedGen" ID="C3150659">Breast-ovarian cancer, familial, susceptibility to, 3</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2023-11-26" SubmissionCount="4">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_058216.3(RAD51C):c.93del (p.Phe32fs) AND Hereditary cancer-predisposing syndrome" Accession="RCV000160936" Version="14">
        <ClassifiedConditionList TraitSetID="13598">
          <ClassifiedCondition DB="MedGen" ID="C0027672">Hereditary cancer-predisposing syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2023-02-20" SubmissionCount="3">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_058216.3(RAD51C):c.93del (p.Phe32fs) AND Fanconi anemia complementation group O" Accession="RCV000205375" Version="11">
        <ClassifiedConditionList TraitSetID="1880">
          <ClassifiedCondition DB="MedGen" ID="C3150653">Fanconi anemia complementation group O</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-12-28" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_058216.3(RAD51C):c.93del (p.Phe32fs) AND not provided" Accession="RCV000212931" Version="8">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2023-05-01" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_058216.3(RAD51C):c.93del (p.Phe32fs) AND multiple conditions" Accession="RCV000576723" Version="2">
        <ClassifiedConditionList TraitSetID="19217">
          <ClassifiedCondition DB="MedGen" ID="C3150659">Breast-ovarian cancer, familial, susceptibility to, 3</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C3150653">Fanconi anemia complementation group O</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2017-06-02" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_058216.3(RAD51C):c.93del (p.Phe32fs) AND Ovarian neoplasm" Accession="RCV001195009" Version="1">
        <ClassifiedConditionList TraitSetID="6377">
          <ClassifiedCondition DB="MedGen" ID="C0919267">Ovarian neoplasm</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2020-02-28" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_058216.3(RAD51C):c.93del (p.Phe32fs) AND Hereditary breast ovarian cancer syndrome" Accession="RCV000587817" Version="1">
        <ClassifiedConditionList TraitSetID="7920">
          <ClassifiedCondition DB="MedGen" ID="C0677776">Hereditary breast ovarian cancer syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2017-11-22" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_058216.3(RAD51C):c.93del (p.Phe32fs) AND not specified" Accession="RCV001001178" Version="8">
        <ClassifiedConditionList TraitSetID="9590">
          <ClassifiedCondition DB="MedGen" ID="CN169374">not specified</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-04-07" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-12-28" NumberOfSubmissions="14" NumberOfSubmitters="14" DateCreated="2013-09-13" MostRecentSubmission="2024-06-17">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">20400964</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21616938</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21990120</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23176254</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24800917</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26556299</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26681312</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27433846</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">28802053</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29278735</ID>
        </Citation>
        <DescriptionHistory Dated="2018-05-29">
          <Description>Pathogenic, risk factor</Description>
        </DescriptionHistory>
        <DescriptionHistory Dated="2017-02-06">
          <Description>Pathogenic</Description>
        </DescriptionHistory>
        <DescriptionHistory Dated="2017-02-06">
          <Description>risk factor</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="19217" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6648" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">RAD51C-Related Breast/Ovarian Cancer</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Breast-ovarian cancer, familial 3</ElementValue>
                <XRef ID="Breast-ovarian+cancer%2C+familial+3/7867" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Breast-ovarian cancer, familial, susceptibility to, 3</ElementValue>
                <XRef ID="MONDO:0013253" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">BROVCA3</ElementValue>
                <XRef Type="MIM" ID="613399" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <XRef ID="145" DB="Orphanet" />
              <XRef ID="C3150659" DB="MedGen" />
              <XRef ID="MONDO:0013253" DB="MONDO" />
              <XRef Type="MIM" ID="613399" DB="OMIM" />
            </Trait>
            <Trait ID="6757" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Fanconi anemia complementation group O</ElementValue>
                <XRef ID="MONDO:0013248" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">FANCO</ElementValue>
                <XRef Type="MIM" ID="613390" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15656" />
                <XRef ID="15656" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA.</Attribute>
                <XRef ID="NBK1401" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301575</ID>
                <ID Source="BookShelf">NBK1401</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="FARF, 2008">
                <URL>http://www.fanconi.org/images/uploads/other/Guidelines_for_Diagnosis_and_Management.pdf</URL>
                <CitationText>Fanconi Anemia Research Fund, Guidelines for Diagnosis and Management (3rd Ed.), 2008 (See 2020 Update)</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="FARF, 2020">
                <URL>https://www.fanconi.org/explore/clinical-care-guidelines</URL>
                <CitationText>Fanconi Anemia Clinical Care Guidelines, Fifth Edition.</CitationText>
              </Citation>
              <XRef ID="84" DB="Orphanet" />
              <XRef ID="C3150653" DB="MedGen" />
              <XRef ID="MONDO:0013248" DB="MONDO" />
              <XRef Type="MIM" ID="613390" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="7920" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="16761" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Hereditary breast ovarian cancer syndrome</ElementValue>
                <XRef ID="MONDO:0003582" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Breast and ovarian cancer</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary breast and ovarian cancer syndrome</ElementValue>
                <XRef ID="D061325" DB="MeSH" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary breast and ovarian cancer syndrome (HBOC)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary breast and/or ovarian cancer syndrome</ElementValue>
                <XRef ID="145" DB="Orphanet" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary breast and ovarian cancer</ElementValue>
                <XRef ID="UWMG_4506306" DB="CSER _CC_NCGL, University of Washington" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">HBOC</ElementValue>
                <XRef ID="GTR000500933" DB="Genetic Testing Registry (GTR)" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000021468" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000514601" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509982" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000021517" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000017874" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507653" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552245" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501981" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520887" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509983" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558867" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000521909" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522160" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000505644" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552183" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528915" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591268" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551441" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522278" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522559" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000508566" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552302" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000508948" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562228" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530120" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000503369" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509001" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551448" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551440" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569916" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522161" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528916" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000604264" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530118" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000017876" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000325401" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509980" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000502103" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000595973" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000508956" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509985" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000523320" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000527942" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558503" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509984" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520394" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000521908" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558910" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530028" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000330054" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000325409" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512816" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000521499" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520072" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507764" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592450" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509002" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509978" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000500933" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530202" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000561859" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520071" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522159" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512699" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15010" />
                <XRef ID="15010" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.</Attribute>
                <XRef ID="NBK1247" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301425</ID>
                <ID Source="BookShelf">NBK1247</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACS, 2007">
                <ID Source="PubMed">17392385</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="PubMed">20065170</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2003">
                <ID Source="PubMed">12692171</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="review" Abbrev="Stratton and Rahman, 2008">
                <ID Source="PubMed">18163131</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2007">
                <ID Source="PubMed">17508274</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19305347</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Phillips et al., 2013">
                <ID Source="PubMed">23918944</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Domchek et al., 2010">
                <ID Source="pmc">2948529</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014 [Archived]">
                <ID Source="PubMed">24366376</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2013">
                <ID Source="PubMed">23188549</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014">
                <ID Source="PubMed">24366402</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2013">
                <ID Source="PubMed">24432435</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2021">
                <ID Source="PubMed">33410258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2022">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31429903</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479213</ID>
                <ID Source="BookShelf">NBK545867</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Hereditary-Breast-Ovarian-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg122</URL>
                <CitationText>UK NICE Clinical guideline (CG122), Ovarian cancer: recognition and initial management, 2023</CitationText>
              </Citation>
              <XRef ID="145" DB="Orphanet" />
              <XRef ID="C0677776" DB="MedGen" />
              <XRef ID="D061325" DB="MeSH" />
              <XRef ID="MONDO:0003582" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="1881" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6648" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">RAD51C-Related Breast/Ovarian Cancer</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Breast-ovarian cancer, familial 3</ElementValue>
                <XRef ID="Breast-ovarian+cancer%2C+familial+3/7867" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Breast-ovarian cancer, familial, susceptibility to, 3</ElementValue>
                <XRef ID="MONDO:0013253" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">BROVCA3</ElementValue>
                <XRef Type="MIM" ID="613399" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <XRef ID="145" DB="Orphanet" />
              <XRef ID="C3150659" DB="MedGen" />
              <XRef ID="MONDO:0013253" DB="MONDO" />
              <XRef Type="MIM" ID="613399" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="1880" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6757" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Fanconi anemia complementation group O</ElementValue>
                <XRef ID="MONDO:0013248" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">FANCO</ElementValue>
                <XRef Type="MIM" ID="613390" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15656" />
                <XRef ID="15656" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA.</Attribute>
                <XRef ID="NBK1401" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301575</ID>
                <ID Source="BookShelf">NBK1401</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="FARF, 2008">
                <URL>http://www.fanconi.org/images/uploads/other/Guidelines_for_Diagnosis_and_Management.pdf</URL>
                <CitationText>Fanconi Anemia Research Fund, Guidelines for Diagnosis and Management (3rd Ed.), 2008 (See 2020 Update)</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="FARF, 2020">
                <URL>https://www.fanconi.org/explore/clinical-care-guidelines</URL>
                <CitationText>Fanconi Anemia Clinical Care Guidelines, Fifth Edition.</CitationText>
              </Citation>
              <XRef ID="84" DB="Orphanet" />
              <XRef ID="C3150653" DB="MedGen" />
              <XRef ID="MONDO:0013248" DB="MONDO" />
              <XRef Type="MIM" ID="613390" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9590" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="16789" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">AllHighlyPenetrant</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">not specified</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not specified' was created for use in ClinVar so that submitters can convey the concept that a variant is benign, likely benign, or of uncertain significance for an unspecified set of disorders.  This usage was introduced in 2014 to replace AllHighlyPenetrant.</Attribute>
              </AttributeSet>
              <XRef ID="CN169374" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="6377" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="5713" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Ovarian tumor</ElementValue>
                <XRef ID="HP:0100615" DB="Human Phenotype Ontology" />
                <XRef ID="123843001" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neoplasm of ovary</ElementValue>
                <XRef ID="123843001" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ovarian Neoplasms</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Ovarian neoplasm</ElementValue>
                <XRef ID="HP:0100615" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0021068" DB="MONDO" />
              </Name>
              <Citation Type="general" Abbrev="NACB, 2008">
                <ID Source="PubMed">19042984</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2012">
                <ID Source="PubMed">22964825</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2013">
                <ID Source="PubMed">23188549</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2021">
                <ID Source="PubMed">33410258</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2018">
                <ID Source="PubMed">29450531</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg122</URL>
                <CitationText>UK NICE Clinical guideline (CG122), Ovarian cancer: recognition and initial management, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2024">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer, 2024</CitationText>
              </Citation>
              <XRef ID="C0919267" DB="MedGen" />
              <XRef ID="D010051" DB="MeSH" />
              <XRef ID="MONDO:0021068" DB="MONDO" />
              <XRef Type="primary" ID="HP:0100615" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
          <TraitSet ID="13598" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="18746" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Neoplastic Syndromes, Hereditary</ElementValue>
                <XRef ID="D009386" DB="MeSH" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hereditary cancer-predisposing syndrome</ElementValue>
                <XRef ID="699346009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Tumor predisposition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cancer predisposition</ElementValue>
                <XRef ID="Hereditary+Cancer/3345" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary Cancer Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary neoplastic syndrome</ElementValue>
                <XRef ID="MONDO:0015356" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="19921" />
                <XRef ID="19921" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="general" Abbrev="IARC, 2008">
                <ID Source="pmc">3075918</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <XRef ID="140162" DB="Orphanet" />
              <XRef ID="C0027672" DB="MedGen" />
              <XRef ID="D009386" DB="MeSH" />
              <XRef ID="MONDO:0015356" DB="MONDO" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="50821" SubmissionDate="2019-08-21" DateLastUpdated="2019-09-08" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="602774.0007_BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 3" title="RAD51C, 1-BP DEL, 93G_BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 3" />
        <ClinVarAccession Accession="SCV000045557" DateUpdated="2019-09-08" DateCreated="2013-04-04" Type="SCV" Version="3" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2011-08-15">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>risk factor</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In 3 women from a Finnish family with breast-ovarian cancer-3 (613399), Pelttari et al. (2011) identified a heterozygous 1-bp deletion (93delG) in exon 1 of the RAD51C gene, resulting in a frameshift and premature termination (Phe32SerfsTer8). The deletion was also found in 2 additional family members with skin cancer (1 male and 1 female) and in 2 unaffected male family members. A woman with ovarian cancer from another Finnish family was also found to carry the 93delG mutation. Her mother, who had ovarian cancer, was not available for study. Three unaffected family members, 2 of whom were women, also carried the mutation. These 2 families were part of a larger cohort of 277 Finnish families with breast or ovarian cancer. Screening of additional cohorts identified the 93delG mutation in 2 of 409 unselected ovarian cancer patients and in 2 (0.2%) of 1,279 controls. The mutation was also found in 2 of 686 unselected breast cancer patients from the Tampere region of Finland, but not in 807 controls from this region.</Attribute>
              <Citation>
                <ID Source="PubMed">21616938</ID>
              </Citation>
              <XRef DB="OMIM" ID="613399" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="RAD51C" />
          </GeneList>
          <Name>RAD51C, 1-BP DEL, 93G</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">1-BP DEL, 93G</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="602774.0007" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 3</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2282736" SubmissionDate="2019-08-05" DateLastUpdated="2020-02-10" DateCreated="2020-02-10">
        <ClinVarSubmissionID localKey="2272795|MedGen:CN169374" submittedAssembly="not applicable" />
        <ClinVarAccession Accession="SCV001158330" DateUpdated="2020-02-10" DateCreated="2020-02-10" Type="SCV" Version="1" SubmitterName="ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories" OrgID="25969" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-04-07">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The RAD51C c.93delG; p.Phe32fs variant (rs730881942) is reported in the literature in individuals with breast and/or ovarian cancer, prostate cancer, soft tissue sarcoma, or hematologic cancer (Pelttari 2011, Pritchard 2016, Schrader 2016, Susswein 2016). This variant is reported as pathogenic by multiple laboratories in ClinVar (Variation ID: 182847). It is found in the general population with an overall allele frequency of 0.005% (13/282860 alleles) in the Genome Aggregation Database. This variant causes a frameshift by deleting a single nucleotide, so it is predicted to result in a truncated protein or mRNA subject to nonsense-mediated decay. Based on available information, this variant is considered to be pathogenic. REFERENCES Pelttari LM et al. RAD51C is a susceptibility gene for ovarian cancer. Hum Mol Genet. 2011 Aug 15;20(16):3278-88. Pritchard CC et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med. 2016 Aug 4;375(5):443-53. Schrader KA et al. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. JAMA Oncol. 2016 Jan;2(1):104-11. Susswein LR et al. Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. Genet Med. 2016 Aug;18(8):823-32.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ARUP Molecular Germline Variant Investigation Process</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/w2yp3qyt/arup_molecular_germline_variant_investigation_process.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000017.10:g.56770097delG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not specified</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="CN169374" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>Aug 2019 ARUP</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4956490" SubmissionDate="2022-04-25" DateLastUpdated="2022-06-24" DateCreated="2022-06-24">
        <ClinVarSubmissionID localKey="NM_058216.1:c.93delG|MedGen:C0027672" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002530035" DateUpdated="2022-06-24" DateCreated="2022-06-24" Type="SCV" Version="1" SubmitterName="Sema4, Sema4" OrgID="500057" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-01-27">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">21616938</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26681312</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27433846</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23176254</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20400964</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Sema4 Curation Guidelines</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/cy0kpury/sema4_variant_curation_guidelines-clinvar_april_2022.docx</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="RAD51C" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_058216.1:c.93delG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <Comment>The RAD51C c.93delG (p.F32SfsX8) variant has been reported in heterozygosity in numerous individuals and families with breast and/or ovarian cancer (PMID: 21616938, 26681312). This variant has also been identified in at least one individual with prostate cancer (PMID: 27433846). This variant has been reported as founder mutation in the Finnish population (PMID: 21616938, 23176254). This variant causes a frameshift at amino acid 32 that results in premature termination 8 amino acids downstream. At this location, nonsense-mediated decay is predicted to occur, resulting in a loss of gene function. Loss-of-function variants in RAD51C are known to be pathogenic (PMID: 20400964). This variant was observed in 5/25114 chromosomes in the Finnish population according to the Genome Aggregation Database (http://gnomad.broadinstitute.org, PMID: 32461654). This variant has been reported in ClinVar (Variation ID: 182847). Based on the current evidence available, this variant is interpreted as pathogenic.</Comment>
        <SubmissionNameList>
          <SubmissionName>SUB11360768</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5059007" SubmissionDate="2022-09-27" DateLastUpdated="2023-04-01" DateCreated="2023-04-01">
        <ClinVarSubmissionID localKey="BCLV000287|MedGen:C3150659" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002589007" DateUpdated="2023-04-01" DateCreated="2023-04-01" Type="SCV" Version="1" SubmitterName="BRCAlab, Lund University" OrgID="508740" OrganizationCategory="laboratory" OrgAbbreviation="BRCAlab" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-08-26">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <FamilyData NumFamiliesWithVariant="13" />
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="RAD51C" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000017.10:g.56770097del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C3150659" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SWEA001</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2239764" SubmissionDate="2023-12-22" DateLastUpdated="2024-01-06" DateCreated="2020-01-05">
        <ClinVarSubmissionID localKey="S3936|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001134795" DateUpdated="2024-01-06" DateCreated="2020-01-05" Type="SCV" Version="4" SubmitterName="Quest Diagnostics Nichols Institute San Juan Capistrano" OrgID="500110" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-06-13">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">21616938</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26556299</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26681312</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27433846</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24800917</ID>
          </Citation>
          <Comment>This frameshift variant causes the premature termination of RAD51C protein synthesis. In addition, it has been reported in affected individuals with breast, ovarian and prostate cancer in the published literature (PMIDs: 21616938 (2011), 24800917 (2014), 26556299 (2016), 26681312 (2015), and 27433846 (2016)). Based on the available information, this variant is classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Quest Diagnostics criteria</Attribute>
          <Citation>
            <ID Source="PubMed">26467025</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_058216.2:c.93del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14108248</SubmissionName>
          <SubmissionName>SUB6975398</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="484423" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2016-01-31">
        <ClinVarSubmissionID localKey="665291|MedGen:C3150653" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000259467" DateUpdated="2024-02-20" DateCreated="2016-01-31" Type="SCV" Version="11" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-12-28">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">20400964</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21990120</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24800917</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29278735</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21616938</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27433846</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21616938</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24800917</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27433846</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Phe32Serfs*8) in the RAD51C gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in RAD51C are known to be pathogenic (PMID: 20400964, 21990120, 24800917, 29278735). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This premature translational stop signal has been observed in individual(s) with breast and/or ovarian cancer, prostate cancer (PMID: 21616938, 27433846). It is commonly reported in individuals of Finnish ancestry (PMID: 21616938, 24800917, 27433846). ClinVar contains an entry for this variant (Variation ID: 182847). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="RAD51C" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000017.10:g.56770094del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C3150653" Type="CUI" />
          </Trait>
        </TraitSet>
        <Citation Type="general">
          <ID Source="PubMed">28492532</ID>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200314</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="386255" SubmissionDate="2024-04-24" DateLastUpdated="2024-05-01" DateCreated="2015-03-24">
        <ClinVarSubmissionID localKey="a91947|MedGen:C0027672" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000215256" DateUpdated="2024-05-01" DateCreated="2015-03-24" Type="SCV" Version="7" SubmitterName="Ambry Genetics" OrgID="61756" OrganizationCategory="laboratory" OrgAbbreviation="Ambry" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-03-31">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">21616938</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23176254</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26681312</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27433846</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">28802053</ID>
          </Citation>
          <Comment>The c.93delG pathogenic mutation, located in coding exon 1 of the RAD51C gene, results from a deletion of one nucleotide at position 93, causing a translational frameshift with a predicted alternate stop codon (p.F32Sfs*8). This mutation has been identified in a Finnish breast/ovarian cancer kindred as well as multiple ovarian cancer only families to date (Pelttari LM et al. Hum. Mol. Genet. 2011 Aug;20:3278-88). This same group did not find the c.93delG alteration in a group of 1083 prostate cancer patients and 802 colorectal cancer patients, leading the authors to conclude that this mutation does not predispose to prostate or colorectal cancer (Pelttari LM et al. BMC Cancer. 2012;12:552). In a different prostate cancer cohort, this alteration was identified in 1/692 men with metastatic prostate cancer who were unselected for family history of cancer or age at diagnosis (Pritchard CC et al. N. Engl. J. Med. 2016 Aug;375:443-53). In addition, this alteration was identified in 2/10030 consecutive patients referred for evaluation by an NGS hereditary cancer panel (Susswein LR et al. Genet. Med. 2016 08;18:823-32). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Ambry Variant Classification Scheme 2023</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/i9igeqse/ambry_variant_classification_scheme_2023.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="RAD51C" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_058216.1:c.93delG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>All AVA3 Novel and Update Variants_103122</SubmissionName>
          <SubmissionName>FinalClinVarSubmissionFile_20140101to20240315_ava3_1</SubmissionName>
          <SubmissionName>NonExomeUpdate_081220AmbryReport</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7853102" SubmissionDate="2024-06-05" DateLastUpdated="2024-06-17" DateCreated="2023-12-30">
        <ClinVarSubmissionID localKey="NM_058216.3:c.93del|OMIM:613399" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004207914" DateUpdated="2024-06-17" DateCreated="2023-12-30" Type="SCV" Version="2" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" OrgAbbreviation="BCM: BMGL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-11-26">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_058216.3:c.93del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613399" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GA_HC_20231102_20240331</SubmissionName>
          <SubmissionName>SUB13856327</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1366181" SubmissionDate="2018-01-25" DateLastUpdated="2018-03-17" DateCreated="2018-03-17">
        <ClinVarSubmissionID localKey="NM_058216.1:c.93delG|MedGen:C0677776" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000699829" DateUpdated="2018-03-17" DateCreated="2018-03-17" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-11-22">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">21616938</ID>
          </Citation>
          <Comment>Variant summary: The RAD51C c.93delG (p.Phe32SerfsX8) variant results in a premature termination codon, predicted to cause a truncated or absent RAD51C protein due to nonsense mediated decay, which are commonly known mechanisms for disease. One in silico tool predicts a damaging outcome for this variant. This variant was found in 15/250416 control chromosomes at a frequency of 0.0000599, which does not exceed the estimated maximal expected allele frequency of a pathogenic RAD51C variant (0.0000625). This variant has also been reported in multiple families and individuals with breast and/or ovarian cancer and based on haplotype analysis authors concluded that it is likely a founder mutation in the Finnish population that is associated with moderate-to-high risk susceptibility for ovarian cancer (Pelttari 2011). The founder effect can also explain the higher occurrence of the variant in this population (gnomAD 5/22298 Finnish European). The variant was also found in a patient with ovarian cancer in a different population (Susswein 2016). Truncations downstream of this position have been classified as pathogenic by our laboratory (e.g. c.97C&gt;T (p.Gln33X), c.397C&gt;T (p.Gln133X), c.577C&gt;T (p.Arg193X)). In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation Type="general">
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
            <CitationText>LabCorp Variant Classification Summary - May 2015.docx</CitationText>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="RAD51C" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <XRefList>
            <XRef DB="dbSNP" ID="730881942" Type="rsNumber" />
          </XRefList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_058216.1:c.93delG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0677776" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2016-2017-variants</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2692726" SubmissionDate="2020-02-28" DateLastUpdated="2020-06-28" DateCreated="2020-06-28">
        <ClinVarSubmissionID localKey="RAD51C_000048|OMIM:167000" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001365242" DateUpdated="2020-06-28" DateCreated="2020-06-28" Type="SCV" Version="1" SubmitterName="Leiden Open Variation Database" OrgID="506264" OrganizationCategory="other" OrgAbbreviation="LOVD" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-02-28">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">21616938</ID>
          </Citation>
          <Comment>Curator: Arleen D. Auerbach. Submitter to LOVD: Johan den Dunnen.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="RAD51C" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NM_058216.1:c.93del</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000017.10:g.56770097del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="167000" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB7062991</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1328944" SubmissionDate="2017-06-22" DateLastUpdated="2022-12-24" DateCreated="2018-01-07">
        <ClinVarSubmissionID localKey="297760|OMIM:613390;613399" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000677786" DateUpdated="2022-12-24" DateCreated="2018-01-07" Type="SCV" Version="2" SubmitterName="Counsyl" OrgID="320494" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-06-02">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">21616938</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Counsyl Autosomal Dominant Disease Classification criteria (2015)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/qikq0wz6/counsyl_autosomal_dominant_disease_classification_criteria_2015__v1_4_2_.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="RAD51C" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_058216.1:c.93delG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613390" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613399" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB2805501</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="377344" SubmissionDate="2023-05-10" DateLastUpdated="2023-05-13" DateCreated="2015-02-24">
        <ClinVarSubmissionID localKey="GDXSV:270068" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV000211643" DateUpdated="2023-05-13" DateCreated="2015-02-24" Type="SCV" Version="17" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-05-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 23176254, 27806231, 25470109, 28152038, 21616938, 23117857, 24800917, 27433846, 26681312, 28874143, 28802053, 26556299, 26689913, 32107557, 34923718, 35053526, 35626031, 29922827, 28888541)</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification Process June 2021</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/fc81e176/genedx_variant_classification_process_june_2021.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="RAD51C" />
          </GeneList>
          <VariantType>Deletion</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">GDX:52125</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_058216.1:c.93del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GeneDX_Clinvar_Submission_100_20220413054204</SubmissionName>
          <SubmissionName>GeneDX_Clinvar_Submission_190_20230510054202</SubmissionName>
          <SubmissionName>SUB5098196</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7519317" SubmissionDate="2023-07-25" DateLastUpdated="2023-07-29" DateCreated="2023-07-29">
        <ClinVarSubmissionID localKey="100097875|OMIM:613399" />
        <ClinVarAccession Accession="SCV004019948" DateUpdated="2023-07-29" DateCreated="2023-07-29" Type="SCV" Version="1" SubmitterName="Myriad Genetics, Inc." OrgID="507240" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-04-05">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Myriad Autosomal Dominant, Autosomal Recessive and X-Linked Classification Criteria (2023)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/8ufcwsf2/myriad_genetics_classification_criteria_2023.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="RAD51C" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="hg19" Chr="17" alternateAllele="G" referenceAllele="GG" start="56770096" stop="56770097" />
          </Location>
          <OtherNameList>
            <Name Type="SubmitterVariantId">100097875</Name>
          </OtherNameList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613399" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13707487</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1348587" SubmissionDate="2024-01-25" DateLastUpdated="2024-02-14" DateCreated="2018-02-19">
        <ClinVarSubmissionID localKey="Db4KrQBSZeoE7-orUyypka712FHjXeAkngQ1FY-Pn5U|MedGen:C0027672" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000691291" DateUpdated="2024-02-14" DateCreated="2018-02-19" Type="SCV" Version="4" SubmitterName="Color Diagnostics, LLC DBA Color Health" OrgID="505849" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-02-20">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">21616938</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27433846</ID>
          </Citation>
          <Comment>This variant deletes 1 nucleotide in exon 1 of the RAD51C gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in an individual affected with familial ovarian cancer and another individual affected breast cancer with multiple relatives affected with breast or ovarian cancer (PMID: 21616938). This variant has also been observed in an individual with prostate cancer (PMID: 27433846). This variant has been identified in 13/282860 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of RAD51C function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <TypePlatform>NGS</TypePlatform>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="RAD51C" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_058216.3:c.93del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>Color Genomics - ClinVar Submission - May2020 - SUB747</SubmissionName>
          <SubmissionName>SUB10927044</SubmissionName>
          <SubmissionName>SUB14171678</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1328944" TraitType="Disease" MappingType="XRef" MappingValue="613399" MappingRef="OMIM">
        <MedGen CUI="C3150659" Name="Breast-ovarian cancer, familial, susceptibility to, 3" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2692726" TraitType="Disease" MappingType="XRef" MappingValue="167000" MappingRef="OMIM">
        <MedGen CUI="C1140680" Name="Ovarian cancer" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1348587" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2239764" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2282736" TraitType="Disease" MappingType="Name" MappingValue="not specified" MappingRef="Preferred">
        <MedGen CUI="CN169374" Name="not specified" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1366181" TraitType="Disease" MappingType="XRef" MappingValue="C0677776" MappingRef="MedGen">
        <MedGen CUI="C0677776" Name="Hereditary breast ovarian cancer syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7519317" TraitType="Disease" MappingType="XRef" MappingValue="613399" MappingRef="OMIM">
        <MedGen CUI="C3150659" Name="Breast-ovarian cancer, familial, susceptibility to, 3" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="484423" TraitType="Disease" MappingType="XRef" MappingValue="C3150653" MappingRef="MedGen">
        <MedGen CUI="C3150653" Name="Fanconi anemia complementation group O" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4956490" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="386255" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5059007" TraitType="Disease" MappingType="XRef" MappingValue="C3150659" MappingRef="MedGen">
        <MedGen CUI="C3150659" Name="Breast-ovarian cancer, familial, susceptibility to, 3" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1328944" TraitType="Disease" MappingType="XRef" MappingValue="613390" MappingRef="OMIM">
        <MedGen CUI="C3150653" Name="Fanconi anemia complementation group O" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="377344" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7853102" TraitType="Disease" MappingType="XRef" MappingValue="613399" MappingRef="OMIM">
        <MedGen CUI="C3150659" Name="Breast-ovarian cancer, familial, susceptibility to, 3" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="50821" TraitType="Disease" MappingType="Name" MappingValue="BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 3" MappingRef="Preferred">
        <MedGen CUI="C3150659" Name="Breast-ovarian cancer, familial, susceptibility to, 3" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

